(2S)-6-amino-2-[[(2S)-6-amino-2-[[(2S)-6-amino-2-[[(2S)-6-amino-2-[[(2S)-2-[[(2R)-3-[2,3-di(hexadecanoyloxy)propylsulfanyl]-2-(hexadecanoylamino)propanoyl]amino]-3-hydroxypropanoyl]amino]hexanoyl]amino]hexanoyl]amino]hexanoyl]amino]hexanoic acid | 112208-00-1

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: (2S)-6-amino-2-[[(2S)-6-amino-2-[[(2S)-6-amino-2-[[(2S)-6-amino-2-[[(2S)-2-[[(2R)-3-[2,3-di(hexadecanoyloxy)propylsulfanyl]-2-(hexadecanoylamino)propanoyl]amino]-3-hydroxypropanoyl]amino]hexanoyl]amino]hexanoyl]amino]hexanoyl]amino]hexanoic acid
• CAS: 112208-00-1
• 化学式: C₈₁H₁₅₆N₁₀O₁₃S
• 分子量: 1510.2
• InChiKey: OEDPHAKKZGDBEV-GFPBKZJXSA-N

物化性质

• 沸点：
  1408.0±65.0 °C(Predicted)
• 密度：
  1.054±0.06 g/cm3(Predicted)
• 溶解度：
  在 50% 乙醇/水中的溶解度为 1 mg/ml

计算性质

• 辛醇/水分配系数(LogP)：
  16.1
• 重原子数：
  105
• 可旋转键数：
  80
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.89
• 拓扑面积：
  414
• 氢给体数：
  12
• 氢受体数：
  18

制备方法与用途

用途

本品主要用于实验室有机合成中和化工医药研发过程中。

生物活性

Pam3CSK4 是一种 Toll 样受体 1/2 (TLR1/2) 激动剂，对人 TLR1/2 的 EC50 值为 0.47 ng/mL。它是一种识别三酰基脂肽的 TLR1/2 异二聚体。

体外研究

Pam3CSK4 (1 μg/mL) 能增强由粒细胞-巨噬细胞集落刺激因子（GM-CSF）诱导的中性粒细胞对甲氧西林耐药金黄色葡萄球菌的抗菌功能。

体内研究

Pam3CSK4 在小鼠体内的研究结果显示，通过腹腔注射 (i.p.) 每日一次连续给药 9 天，剂量为 5 mg/kg，可改变新生小鼠的大脑、脾脏和肝脏重量。具体表现为：从出生后第 3 天到第 11 天反复给药，到了第 12 天，与无内毒素的生理盐水对照组相比，大脑重量减少；同时，前脑和小脑分子层中的灰质、白质体积减小，并伴随脾脏和肝脏重量增加。动物模型为 C57BL/6野生型母鼠和 B6.129-Tlr2tm1Kir/J (TLR2 缺陷) 小鼠。

文献信息

• [EN] ANTAGONISTS OF THE TOLL-LIKE RECEPTOR 1/2 COMPLEX<br/>[FR] ANTAGONISTES DU COMPLEXE DE RÉCEPTEUR 1/2 DE TYPE TOLL
  申请人：UNIV COLORADO REGENTS

  公开号：WO2014022287A1

  公开（公告）日：2014-02-06

  Provided are compounds, compositions and methods for treating Toll-like receptor 1/2 complex (TLRI/2) related inflammatory disorders. Small molecules, based on the benzotropolone scaffold, capable of influencing downstream signaling are dislcosed as well as methods of making and modifying these molecules. Also provided are methods for treating a subject for a clinical condition associated with Toll¬ like receptor complex 1/2 activation, comprising administering to the subject an effective amount of a benzotropolone compound.

  提供了用于治疗Toll样受体1/2复合物（TLR1/2）相关炎症性疾病的化合物、组合物和方法。基于苯并三酮骨架的小分子，能够影响下游信号传导，以及制备和修改这些分子的方法也已披露。还提供了用于治疗与Toll样受体复合物1/2激活相关的临床状况的方法，包括向受试者施用有效量的苯并三酮化合物。
• [EN] METHODS AND COMPOSITIONS FOR TREATING ALLERGY AND INFLAMMATORY DISEASES<br/>[FR] MÉTHODES ET COMPOSITIONS DE TRAITEMENT D'ALLERGIE ET LES MALADIES INFLAMMATOIRES
  申请人：BAYLOR RES INST

  公开号：WO2015187637A1

  公开（公告）日：2015-12-10

  Described herein are therapeutic approaches with immune modifiers of the Th2 pathway for the treatment of allergic and inflammatory diseases. Aspects of the disclosure relate to methods for decreasing Th2-type cell responses in a subject in need thereof comprising administering to the subject a therapeutically effective amount of an anti-Dectin-1 antibody or antigen binding fragment thereof operatively linked to a TLR agonist.

  本文描述了使用Th2通路的免疫调节剂治疗过敏和炎症性疾病的治疗方法。其中，揭示的方面涉及降低需要减少Th2型细胞反应的受试者的方法，包括向受试者施用与TLR激动剂操作性连接的抗Dectin-1抗体或抗原结合片段的治疗有效剂量。
• Molecular Imaging of Cancer Cells In Vivo
  申请人：Morse David L.

  公开号：US20140161725A1

  公开（公告）日：2014-06-12

  Cellular targets on cancer cells have been identified that can be used with targeted molecular imaging to detect the cancer cells in vivo. Non-invasive methods for detecting cancer cells, such as metastasized cancer cells, are therefore provided. Also provided are compositions and kits for use in the disclosed methods.

  已经确定了可用于与靶向分子成像结合以在体内检测癌细胞的癌细胞细胞靶点。因此提供了用于检测癌细胞的非侵入性方法，例如转移性癌细胞。还提供了用于所述方法的组合物和试剂盒。
• ANTAGONISTS OF THE TOLL-LIKE RECEPTOR 1/2 COMPLEX
  申请人：THE REGENTS OF THE UNIVERSITY OF COLORADO, a body corporate

  公开号：US20150251987A1

  公开（公告）日：2015-09-10

  Provided are compounds, compositions and methods for treating Toll-like receptor 1/2 complex (TLRI/2) related inflammatory disorders. Small molecules, based on the benzotropolone scaffold, capable of influencing downstream signaling are disclosed as well as methods of making and modifying these molecules. Also provided are methods for treating a subject for a clinical condition associated with Toll-like receptor complex 1/2 activation, comprising administering to the subject an effective amount of a benzotropolone compound.

  提供了用于治疗Toll样受体1/2复合物（TLRI/2）相关炎症性疾病的化合物、组合物和方法。公开了基于苯并三环酮支架的小分子，能够影响下游信号传导，以及制备和修改这些分子的方法。还提供了用于治疗与Toll样受体复合物1/2激活相关的临床状况的方法，包括向受试者施用有效量的苯并三环酮化合物。
• Arene chromium-carbonyl complexes, method for their preparation of and use thereof as pharmaceuticals
  申请人：Universität zu Köln

  公开号：EP2353597A1

  公开（公告）日：2011-08-10

  The invention relates to novel chromium-carbonyl complexes and a method for the preparation of the latter as well as use of the inventive chromium-carbonyl complexes to inhibit NOD1 and/or NOD2 in the immune system of vertebrates. In a further aspect, the invention relates to the use of the inventive chromium-carbonyl complexes as pharmaceutical active ingredients in a pharmaceutical composition.

  该发明涉及新型铬羰基配合物及其制备方法，以及在脊椎动物免疫系统中抑制NOD1和/或NOD2的创新铬羰基配合物的使用。在进一步的方面，该发明涉及将创新的铬羰基配合物作为药物活性成分用于制备药物组合物。